Received Aug 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Pediatric dose (10 mcg) of Engerix-B was administered to a female adult; Pediatric dose (10 mcg) of Engerix-B was administered to a female adult; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 58-year-old female patient who received HBV (Engerix B 10 mcg) for prophylaxis. On 08-AUG-2025, the patient received the 2nd dose of Engerix B 10 mcg. On 08-AUG-2025, an unknown time after receiving Engerix B 10 mcg, the patient experienced adult use of a child product (Verbatim: Pediatric dose (10 mcg) of Engerix-B was administered to a female adult) and underdose (Verbatim: Pediatric dose (10 mcg) of Engerix-B was administered to a female adult). The outcome of the adult use of a child product and underdose were not applicable. Additional Information: GSK receipt date: 08-AUG-2025 Other HCP reported that a Pediatric dose (10 mcg) of Engerix-B was administered to a female adult that morning on 8th August 2025. She mentioned they needed to get guidance on how to proceed.